Pharming Group (PHAR) Competitors $13.72 -0.97 (-6.57%) Closing price 03:57 PM EasternExtended Trading$13.72 0.00 (0.00%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAR vs. ACLX, ADMA, ARWR, MENS, MIRM, MLTX, MTSR, PTGX, AAPG, and LNTHShould you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Arcellx (ACLX), ADMA Biologics (ADMA), Arrowhead Pharmaceuticals (ARWR), Jyong Biotech (MENS), Mirum Pharmaceuticals (MIRM), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Pharming Group vs. Its Competitors Arcellx ADMA Biologics Arrowhead Pharmaceuticals Jyong Biotech Mirum Pharmaceuticals MoonLake Immunotherapeutics Metsera Protagonist Therapeutics Ascentage Pharma Group International Lantheus Pharming Group (NASDAQ:PHAR) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation. Do institutionals & insiders believe in PHAR or ACLX? 0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 96.0% of Arcellx shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by insiders. Comparatively, 8.4% of Arcellx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor PHAR or ACLX? In the previous week, Pharming Group and Pharming Group both had 7 articles in the media. Arcellx's average media sentiment score of 1.18 beat Pharming Group's score of 0.71 indicating that Arcellx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcellx 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is PHAR or ACLX more profitable? Pharming Group has a net margin of -2.19% compared to Arcellx's net margin of -329.93%. Pharming Group's return on equity of -3.31% beat Arcellx's return on equity.Company Net Margins Return on Equity Return on Assets Pharming Group-2.19% -3.31% -1.78% Arcellx -329.93%-43.04%-27.41% Which has more risk & volatility, PHAR or ACLX? Pharming Group has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Which has better valuation and earnings, PHAR or ACLX? Pharming Group has higher revenue and earnings than Arcellx. Pharming Group is trading at a lower price-to-earnings ratio than Arcellx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharming Group$297.20M3.16-$11.84M-$0.13-105.50Arcellx$107.94M38.64-$107.35M-$3.42-21.99 Do analysts rate PHAR or ACLX? Pharming Group currently has a consensus target price of $30.00, indicating a potential upside of 118.74%. Arcellx has a consensus target price of $114.31, indicating a potential upside of 52.00%. Given Pharming Group's higher possible upside, equities research analysts clearly believe Pharming Group is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Arcellx 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.13 SummaryArcellx beats Pharming Group on 8 of the 15 factors compared between the two stocks. Get Pharming Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAR vs. The Competition Export to ExcelMetricPharming GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.01B$3.16B$5.79B$10.19BDividend YieldN/A2.33%5.73%4.61%P/E Ratio-105.507.5356.1422.50Price / Sales3.16454.56538.28122.35Price / Cash198.0444.4425.8129.91Price / Book4.229.6413.256.28Net Income-$11.84M-$53.20M$3.29B$270.38M7 Day Performance-7.33%0.44%0.47%2.70%1 Month Performance17.73%4.26%4.60%5.99%1 Year Performance82.87%9.43%73.42%25.94% Pharming Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHARPharming Group2.2219 of 5 stars$13.72-6.6%$30.00+118.7%+95.7%$1.01B$297.20M-105.50280News CoverageShort Interest ↑ACLXArcellx2.2807 of 5 stars$71.11-2.1%$114.31+60.7%-0.9%$4.03B$107.94M-20.7980Positive NewsADMAADMA Biologics3.6909 of 5 stars$16.42-2.7%$27.67+68.5%-10.9%$4.03B$426.45M19.09530Positive NewsARWRArrowhead Pharmaceuticals4.1529 of 5 stars$27.17-6.6%$43.14+58.8%+38.3%$4.02B$3.55M-21.23400Analyst RevisionMENSJyong BiotechN/A$55.68+6.4%N/AN/A$3.98BN/A0.0031News CoverageHigh Trading VolumeMIRMMirum Pharmaceuticals3.3249 of 5 stars$77.39+1.7%$74.13-4.2%+80.7%$3.82B$336.89M-63.96140Positive NewsAnalyst ForecastInsider TradeMLTXMoonLake Immunotherapeutics2.5081 of 5 stars$61.12+2.8%$74.43+21.8%+2.9%$3.82BN/A-21.992MTSRMetseraN/A$35.10-2.1%$59.00+68.1%N/A$3.77BN/A0.0081Analyst UpgradePTGXProtagonist Therapeutics2.3669 of 5 stars$56.19-7.2%$67.20+19.6%+25.2%$3.77B$434.43M80.27120News CoveragePositive NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeAAPGAscentage Pharma Group InternationalN/A$41.04+1.3%N/AN/A$3.76B$134.35M0.00600Positive NewsHigh Trading VolumeLNTHLantheus4.5396 of 5 stars$53.63-2.0%$91.60+70.8%-49.8%$3.72B$1.53B14.26700Trending NewsAnalyst Forecast Related Companies and Tools Related Companies ACLX Competitors ADMA Competitors ARWR Competitors MENS Competitors MIRM Competitors MLTX Competitors MTSR Competitors PTGX Competitors AAPG Competitors LNTH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAR) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group N.V. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHAR Stock Alerts